FIELD: molecular biology; immunology and medicine.
SUBSTANCE: invention relates to new constructs of T-cell receptors (TCRs) and engineered immunoreactive cells containing them. The subject matter disclosed herein provides methods and compositions for enhancing the immune response to cancer and pathogens. The TCR of the invention binds to antigen in an HLA-independent manner.
EFFECT: invention provides new antigen recognition receptor designs that have consistent efficacy and increased ability to detect low levels of target antigen.
24 cl, 10 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
| MESOTHELINIC CAR RECEPTORS AND USE THEREOF | 2020 |
|
RU2822193C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2016 |
|
RU2752880C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B CELLS, AND THEIR APPLICATION | 2015 |
|
RU2761632C2 |
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO THE T-CELL RECEPTOR β- CONSTANT REGION | 2015 |
|
RU2744046C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| ANTIBODIES TO CHIMERIC ANTIGEN RECEPTORS DERIVED FROM 4G7 | 2020 |
|
RU2826051C2 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
